Updates are available Correction dated 2022-08-09
Click to view Correction: https://doi.org/10.1038/s41591-022-01996-9
-
Authors
Van Gelder, Russell N. http://orcid.org/0000-0001-5368-3659
Chiang, Michael F.
Dyer, Michael A. http://orcid.org/0000-0003-4027-4850
Greenwell, Thomas N.
Levin, Leonard A. http://orcid.org/0000-0002-1399-250X
Wong, Rachel O.
Svendsen, Clive N. http://orcid.org/0000-0001-8696-3446
-
Funding
Funding for this research was provided by:
Research to Prevent Blindness (Unrestricted departmental grant)
- License Information
-
More Information
Article History
Received: 14 February 2022
Accepted: 6 May 2022
First Online: 17 June 2022
Change Date: 9 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-01996-9
Competing interests
: R.N.V.G., R.O.W., M.F.C., C.N.S., M.A.D. and T.N.G. have no competing interests. L.A.L. serves as paid consultant to Pirlenia, Janssen, Roche, Neuoptika, Quark, Perfuse, Genentech, Regenera, Unity, Eyevensys, Santen and Aerie.
